{
    "clinical_study": {
        "@rank": "149530", 
        "acronym": "OPTIMUM", 
        "arm_group": {
            "arm_group_label": "Optim Leads"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, multi-center, actively monitored, long term data collection registry.\n      Any Patient that receives a market released St. Jude Medical (SJM) Optim lead and a\n      compatible market released cardia rhythm management (CRM) implantable pulse generator is\n      eligible for enrollment into the registry."
        }, 
        "brief_title": "Lead Registry for Optim Leads", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Optim Lead Insulation Related Adverse Events", 
        "detailed_description": {
            "textblock": "Patients are enrolled in the registry up to 180 days post implantation of an Optim lead.\n      Patients with Optim\u2122 ICD leads and Quicksite\u00ae/Quickflex\u00ae/Quickflex\u00ae \u00b5/Quartet\u00ae LV leads are\n      followed indefinitely following enrollment. Patients with other Optim leads are followed for\n      a period of 60 months after Optim\u2122 lead implantation.  The follow-up plan for this registry\n      is based on the established follow-up practices currently used by each of the respective\n      registry centers. Patients are followed according to the center's standard follow-up\n      schedule.\n\n      At each office/clinic follow-up visit standard electrical measurements are collected. During\n      system revision in a patient with either Optim\u2122 ICD leads, Quicksite\u00ae, Quickflex\u00ae,\n      Quickflex\u00ae \u00b5 or Quartet\u00ae LV lead, cinefluoroscopy (AP, LAO 45\u00b0 or the best possible LAO\n      view, RAO 45\u00b0 or the best possible RAO view) should be performed at specific study sites.\n      If cinefluoroscopy or chest X-ray is performed according to the site's standard of care then\n      copies of those should be submitted."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient has a standard indication for a CRM implantable pulse generator.\n\n          -  Patient receives a market released SJM Optim lead at implant.\n\n          -  Patient receives a market released CRM implantable pulse generator at implant.\n\n          -  Patient is willing to provide authorization for registry participation.\n\n          -  Complete device implant information, including any Optim lead related adverse event\n             is available\n\n        Exclusion Criteria:\n\n          -  Patient has medical conditions or related factors that would prevent or limit\n             participation (including mechanical tricuspid valves, tricuspid valvular disease, and\n             candidacy for heart transplants within 6 months).\n\n          -  Patient is < 18 years of age.\n\n          -  Patient has a life expectancy of < 2 years (malignancies)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients implanted with market released SJM Optim lead and a compatible market released\n        CRM implantable pulse generator (pacemaker, implantable cardioverter defibrillator (ICD),\n        or cardiac resynchronization therapy device (CRT)) is eligible for enrollment into the\n        registry."
            }
        }, 
        "enrollment": {
            "#text": "14124", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01722188", 
            "org_study_id": "CD0196"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Optim", 
            "Insulation"
        ], 
        "lastchanged_date": "November 2, 2012", 
        "number_of_groups": "1", 
        "official_title": "Optim Lead Insulation Material Registry", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Survival from insulation related adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01722188"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "St. Jude Medical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "St. Jude Medical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2006", 
        "study_design": "Observational Model: Case-Only, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2012"
    }
}